Low-dose dasatinib rescues cardiac function in Noonan syndrome
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Noonan syndrome (NS) is a common autosomal dominant disorder that presents with short stature, craniofacial dysmorphism, and cardiac abnormalities. Activating mutations in the PTPN11 gene encoding for the Src homology 2 (SH2) domain-containing protein tyrosine phosphatase-2 (SHP2) causes approximately 50% of NS cases. In contrast, NS with multiple lentigines (NSML) is caused by mutations that inactivate SHP2, but it exhibits some overlapping abnormalities with NS. Protein zero-related (PZR) is a SHP2-binding protein that is hyper-tyrosyl phosphorylated in the hearts of mice from NS and NSML, suggesting that PZR and the tyrosine kinase that catalyzes its phosphorylation represent common targets for these diseases. We show that the tyrosine kinase inhibitor, dasatinib, at doses orders of magnitude lower than that used for its anticancer activities inhibited PZR tyrosyl phosphorylation in the hearts of NS mice. Low-dose dasatinib treatment of NS mice markedly improved cardiomyocyte contractility and functionality. Remarkably, a low dose of dasatinib reversed the expression levels of molecular markers of cardiomyopathy and reduced cardiac fibrosis in NS and NSML mice. These results suggest that PZR/SHP2 signaling is a common target of both NS and NSML and that low-dose dasatinib may represent a unifying therapy for the treatment of PTPN11 -related cardiomyopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras.
Bennett, A. M., Tang, T. L., Sugimoto, S., Walsh, C. T., & Neel, B. G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7335 · Cited by 397 · cited 1×
“Indeed, SHP2 has been shown to function as an adaptor protein and signal independently of its phosphatase activity (22, 23).”
BackgroundSelf-citationSHP2 sails from physiology to pathology
Tajan, M., de Rocca Serra, A., Valet, P., Edouard, T., & Yart, A. (2015) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2015.08.005 · Cited by 232 · cited 1×
“SHP2 acts primarily as a positive regulator of cell signaling and in virtually all cases its catalytic activity is required for signal propagation (15).”
BackgroundK-Ras V14I recapitulates Noonan syndrome in mice
Hernández-Porras, I., Fabbiano, S., Schuhmacher, A. J., Aicher, A., Cañamero, M., Cámara, J. A., Cussó, L., Desco, M., Heeschen, C., Mulero, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418126111 · Cited by 96 · cited 2×
“It has been shown that inhibitors of the Akt/mTOR pathway can ameliorate HCM in the NSML model (25, 26), whereas, genetic interference with, or pharmacologic inhibition of, MEK/ERK in a NS mouse model suppresses the development of CHD (27–30).”
BackgroundMolecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations
Yu, Z.-H., Zhang, R.-Y., Walls, C. D., Chen, L., Zhang, S., Wu, L., Liu, S., & Zhang, Z.-Y. (2014) · Biochemistry · doi:10.1021/bi5002695 · Cited by 87 · cited 1×
“PTPN11 -asso- ciated SHP2 mutations exist in an “open” conformation (20, 21).”
Background
Cited by
Targeting cellular senescence prevents age-related bone loss in mice
Farr, J. N., Xu, M., Weivoda, M. M., Monroe, D. G., Fraser, D. G., Onken, J. L., Negley, B. A., Sfeir, J. G., Ogrodnik, M. B., Hachfeld, C. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4385 · Cited by 1,182
The role of cellular senescence in ageing and endocrine disease
Khosla, S., Farr, J. N., Tchkonia, T., & Kirkland, J. L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0335-y · Cited by 523
Taurine deficiency as a driver of aging
Singh, P., Gollapalli, K., Mangiola, S., Schranner, D., Yusuf, M. A., Chamoli, M., Shi, S. L., Lopes Bastos, B., Nair, T., Riermeier, A., et al. (2023) · Science · doi:10.1126/science.abn9257 · Cited by 435
Farr, J. N., & Khosla, S. (2019) · Bone · doi:10.1016/j.bone.2019.01.015 · Cited by 263
Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis
Khosla, S., Farr, J. N., & Kirkland, J. L. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02694 · Cited by 130
Metadata
- Authors
- Yi, J.-S., Huang, Y., Kwaczala, A. T., Kuo, I. Y., Ehrlich, B. E., Campbell, S. G., Giordano, F. J., & Bennett, A. M.
- Venue
- JCI Insight
- Published
- 2016-12-08
- Volume
- 1
- Issue
- 20
- Pages
- e90220-e90220
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2560676950
- Cited by
- 48
- References
- 4
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.